Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
出版年份 2018 全文链接
标题
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
作者
关键词
MK-0646, Gemcitabine, Erlotinib, Advanced pancreatic adenocarcinoma
出版物
Journal of Hematology & Oncology
Volume 11, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-05-30
DOI
10.1186/s13045-018-0616-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
- (2016) Linda S. Steelman et al. Aging-US
- A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,KRASWild-Type, Metastatic Colorectal Cancer
- (2015) Francesco Sclafani et al. JNCI-Journal of the National Cancer Institute
- A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,KRASWild-Type, Metastatic Colorectal Cancer
- (2015) Francesco Sclafani et al. JNCI-Journal of the National Cancer Institute
- Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO
- (2014) Philip A. Philip et al. CANCER
- Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
- (2014) S. Di Cosimo et al. CLINICAL CANCER RESEARCH
- NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer
- (2014) Peter M. Ellis et al. Journal of Thoracic Oncology
- Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer
- (2013) Toshihiko Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Insulin-Like Growth Factor 1 Receptor Promotes the Growth and Chemoresistance of Pancreatic Cancer
- (2013) Xiaodong Tian et al. DIGESTIVE DISEASES AND SCIENCES
- KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
- (2013) Stefan Boeck et al. JOURNAL OF GASTROENTEROLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
- (2012) H. L. Kindler et al. ANNALS OF ONCOLOGY
- A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors
- (2012) Diane L. Reidy-Lagunes et al. CANCER
- A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2011) F. Atzori et al. CLINICAL CANCER RESEARCH
- Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy
- (2011) S. T. Kim et al. MOLECULAR CANCER THERAPEUTICS
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidermal Growth Factor Receptor in Pancreatic Cancer
- (2011) Melissa Oliveira-Cunha et al. Cancers
- Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
- (2010) A Gualberto et al. BRITISH JOURNAL OF CANCER
- Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer
- (2010) Gilda da Cunha Santos et al. CANCER
- Insulin-Like Growth Factor Axis Gene Polymorphisms and Clinical Outcomes in Pancreatic Cancer
- (2010) Xiaoqun Dong et al. GASTROENTEROLOGY
- Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer
- (2010) Diane Lauren Reidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells
- (2009) N. Eckstein et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started